Domain Therapeutics and Chime Biologics announce manufacturing agreement
Chime Achieves ISO 27001 Certification to Strengthen Information Security
SHANGHAI, Oct. 26, 2023 /PRNewswire/ -- Chime Biologics, a leading CDMO that enables its partners' success in biologics, and Hope Medicine Inc. (HopeMed), a science-driven, patient-centric, clinical-stage biotech company, announced on September 28 that the companies are collaborating to develop and manufacture the first-in-class monoclonal antibody drug HMI-115.
Chime Biologics, a biologics contract development and manufacturing organization (CDMO), has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.
SHANGHAI, June 30, 2023 /PRNewswire/ -- Chime Biologics, a leading CDMO that enables its partners' success in biologics, announced that it has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.
Chime Biologics, a contract development and manufacturing organization (CDMO), recently received its commercial manufacturing license from China’s National Medical Products Administration (NMPA).
On August 2, 2022 (Beijing time), Chime Biologics, a leading CDMO that enables its partners' success in biologics, announced that it has received the ...
EOC Pharma, an oncology specialty biopharmaceutical company in China, and Chime Biologics, a contract development and manufacturing organization (CDMO), have extended their partnership on the CMC development of EOC202, a recombinant LAG-3 protein for cancer immunotherapy. The extended partnership will enable Chime's world-class biologics development and manufacturing capability and capacity to become part of EOC's engine to fuel the EOC202's clinical development and potential commercial supply in China.
EOC Pharma, an oncology specialty biopharmaceutical company in China, and Chime Biologics, a contract development and manufacturing organization (CDMO), have extended their partnership on the CMC development of EOC202, a recombinant LAG-3 protein for cancer immunotherapy. The extended partnership will enable Chime's world-class biologics development and manufacturing capability and capacity to become part of EOC's engine to fuel the EOC202's clinical development and potential commercial supply in China.